Watch for regulatory submission timing in China and potential ex-China regulatory strategy. The SAFFRON Phase III data (presented at same ESMO congress) also showed positive results in the post-TAGRISSO setting, creating a comprehensive treatment continuum. Monitor partnership dynamics with AstraZeneca and any global regulatory filings.
Price Chart
Executive Summary
HUTCHMED announced positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in first-line EGFR-mutated NSCLC with MET overexpression. The combination met its primary endpoint with a 44% reduction in risk of disease progression or death in the ITT population (median PFS 24.9 vs 13.8 months) and showed a clinically meaningful OS improvement (HR 0.48). HUTCHMED plans to file a supplemental NDA in China for this first-line indication.
Key Facts
- SANOVO Phase III met primary endpoint: PFS HR 0.56 (95% CI 0.43-0.74; p<0.0001) in ITT; median PFS 24.9 vs 13.8 months
- In high MET (IHC 3+) population: PFS HR 0.45 (95% CI 0.31-0.66; p<0.0001); median PFS 24.8 vs 11.1 months
- OS secondary endpoint: HR 0.48 (95% CI 0.33-0.68); median OS 44.5 vs 34.9 months; 3-year survival 67.4% vs 47.4%
- Safety profile manageable; treatment discontinuation due to AEs in 14.8% of combination arm
- HUTCHMED plans to submit supplemental NDA in China for first-line setting
- ORPATHYS is jointly developed with AstraZeneca and commercialized by AstraZeneca
Financial Impact
Positive Phase III data supports label expansion into first-line EGFRm NSCLC with MET overexpression, potentially doubling the addressable patient population for ORPATHYS+TAGRISSO combination. HUTCHMED's market cap is $2.5B; a new first-line indication in China (where ~30-40% of NSCLC patients have EGFR mutations) represents a material revenue opportunity.
Risk Factors
- Regulatory approval in China not guaranteed; supplemental NDA review timeline uncertain
- Competition from other MET-targeted therapies and combination regimens
- Commercial uptake depends on biomarker testing adoption (MET IHC) at diagnosis
- Ex-China regulatory path unclear; current approvals are China-specific
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387851 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $14.34 | awaiting T+20 | — | $13.77 (−3.97%) |
Oct 26, 2026 1d ago | 6-K | $15.41 | awaiting T+20 | — | $13.77 (−10.64%) |
Oct 26, 2026 1d ago | Press Release | $14.50 | awaiting T+20 | — | $13.77 (−5.03%) |
Oct 26, 2026 1d ago | Press Release | $14.34 | awaiting T+20 | — | $13.77 (−3.97%) |
Oct 21, 2026 6d ago | 6-K | $14.37 | awaiting T+20 | — | $13.77 (−4.18%) |
Sep 29, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $13.77 (−2.69%) |
Sep 28, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $13.77 (−2.69%) |
Sep 29, 2026 28d ago | Press Release | $14.63 | awaiting T+20 | — | $13.77 (−5.88%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $13.77 (−0.94%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $13.77 (−1.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers